6533b829fe1ef96bd1289bbd
RESEARCH PRODUCT
In vitro and in vivo anticryptococcal activities of a new pyrazolo-isothiazole derivative
Giovanni M. GiammancoAnna Maria SchimizziGiuseppe PizzoD. ArzeniFrancesco BarchiesiMaria Eleonora MiliciMaurizio ManfriniGiorgio ScaliseChiara Beatrice VicentiniDaniele Gianninisubject
Microbiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaAntifungal AgentsRatónMicrobial Sensitivity TestsPharmacologyMicechemistry.chemical_compoundOral administrationIn vivomedicineAnimalsHumansPharmacology (medical)Cryptococcus neoformansPharmacologyIsothiazolebiologyFungi imperfectibiology.organism_classificationmedicine.diseaseIn vitroThiazolesInfectious DiseaseschemistryCryptococcosisImmunologyCryptococcus neoformansPyrazolesFemaledescription
We investigated the activity of a pyrazolo-isothiazole derivative (G8) against Cryptococcus neoformans. A first screening test showed that G8 at 10 mg/L inhibited the growth of 14 of 15 clinical isolates tested. Killing experiments showed that fungicidal activity was achieved after 8 h of treatment with G8 at concentrations > or =10 mg/L. In a murine model of systemic cryptococcosis, G8 was effective at prolonging survival compared with the controls. Our data indicate that this new derivative has a potential therapeutic role in infections caused by C. neoformans.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2003-01-01 |